Continuous-Release Anti-VEGF for Macular Degeneration Continues to Impress

(MedPage Today) -- SAN ANTONIO--An ocular implant that provided 6 months of continuous-release anti-VEGF therapy achieved vision and anatomic outcomes equivalent to standard monthly intravitreal injections for neovascular age-related macular...